Nabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.com
by Kim Johansen · The Markets DailyStockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $8.45. The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53.
About Nabriva Therapeutics
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- How Much Can You Make in Stocks in One Month?
- 5 Top Rated Dividend Stocks to Consider
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Do S&P 500 Stocks Tell Investors About the Market?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside